05/07/2020 4:36 pm Welcome to isteroids.com - BLOG

Tuesday 01, Jun 2010

  Steroid therapies can be eliminated after transplantation

Posted By
Pin it Share on Tumblr

Steroid therapies can be eliminated after transplantationUse of modern immunosuppressive drugs eliminates the need for steroid therapy as early as one week following a transplant surgery besides maintaining kidney function.

Steve Woodle, MD, chief of UC’s transplant surgery division, principal investigator and designer of the study, said that elimination of a daily dose of steroids after transplant reduces chronic health conditions common to kidney transplant recipients.

This study also involved researchers from the University of Wisconsin; the University of Utah; the Methodist Hospital, Houston; and Weill Cornell Medical College and was funded by Astellas Pharma U.S., Inc.

Friday 28, May 2010

  Abstaining from some immunosuppressive drugs can benefit kidney transplant patients

Posted By
Pin it Share on Tumblr

Abstaining from some immunosuppressive drugs can benefit kidney transplant patientsWithdrawal of certain immunosuppressive drugs after transplantation of the kidney could prolong survival and help in saving a considerable amount of money when compared with keeping patients on these medications for life.

This finding was disclosed in a study that appeared in an issue of the Journal of the American Society Nephrology (JASN).

Funding for this analysis was provided by Wyeth Pharmaceuticals in Collegeville, PA.

Wednesday 06, Jan 2010

  Improved benefits and less organ rejection associated with immunosuppressive combination for heart transplants

Posted By
Pin it Share on Tumblr

10245A new study led by researchers has shown that one particular combination using tacrolimus (TAC or PrografÃ’ also known as FK506) has considerable anti-rejection benefits for patients in context to fighting off rejection of new heart after transplant surgery.

Dr. Jon Kobashigawa, lead author of the study and medical director of the UCLA Heart Transplant Program, said that there has been an absence of definitive clinical trial data comparing commonly used immunosuppressive agents that has suggested the reason for debate for deciding the most advantageous combination therapies for heart transplant recipients.

The list of other study authors included Dr. Leslie W. Miller, University of Minnesota, Minneapolis, MN; Dr. Stuart D. Russell, Johns Hopkins Hospital, Baltimore, MD; Dr. Gregory A. Ewald, Washington University, St. Louis, MO; Dr. Mark J. Zucker, Beth Israel Hospital, Newark, NJ; Dr. L. R. Goldberg, University of Pennsylvania, Philadelphia, PA; Dr. H. J. Eisen, Drexel University, Philadelphia, PA; Kim Salm, RN, D. Tolzman, W. E. Fitzsimmons, PharmD and Dr. M.R. First, Fujisawa Healthcare, Inc., Deerfield, IL; Dr. J. Gao, The EMMES Corporation, Rockville, MD.